Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Norhintal versus enalapril for cardioprotection in Duchenne muscular dystrophy cardiomyopathy
ChiCTR2300075957Phase 3Not yet recruiting
- Sponsor
- West China Second University Hospital
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of enalapril in Duchenne muscular dystrophy (DMD) (2 arms), sponsored by West China Second University Hospital. Primary endpoint: Change in late gadolinium enhancement volume. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
enalapril
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on ChiCTR2300075957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075957.